Tags

Type your tag names separated by a space and hit enter

Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration.

Abstract

PURPOSE

To evaluate the safety and efficacy of intravitreal bevacizumab therapy for early and advanced neovascular age-related macular degeneration (ARMD).

METHODS

A consecutive series of eyes with neovascular ARMD treated with monthly intravitreal injections of bevacizumab (1.25 mg/0.05 ml) as long as there was evidence of activity on fluorescein angiography (FA) and optical coherence tomography (OCT) was included and observed for 6 months. For further analysis they were assigned to either an early (untreated/newly diagnosed) or an advanced (predominantly fibrotic/pre-treated) ARMD group. We examined distance visual acuity (VA) with Early Treatment Diabetic Retinopathy Study (ETDRS) charts and central retinal thickness with OCT, as well as lesion size and safety aspects.

RESULTS

Forty-four patients (44 eyes) were enrolled (21 early lesions, 23 advanced lesions). Mean VA changed from 0.74 logMAR at baseline to 0.68 logMAR at month 6 (P = 0.01). Improvement in VA was statistically significant only in eyes with early lesions (n = 21) from month 1 (P = 0.015) up to month 6 (P = 0.03). The changes in central retinal thickness (CRT) (P < 0.001) and total lesion size (P < 0.001) were significant in both groups (early and advanced) at all time-points during follow-up. No significant ocular or systemic adverse effects were observed.

CONCLUSION

Intravitreal bevacizumab was tolerated well by our patients and we did not identify any apparent short-term safety concerns. We observed stabilization in VA overall, with significant improvement in the early lesion group.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Ophthalmology and Laser Surgery, Rudolf Foundation Clinic, Vienna, Austria. ilse.krebs@wienkav.at

    , , , ,

    Source

    Acta ophthalmologica 87:6 2009 Sep pg 611-7

    MeSH

    Aged
    Aged, 80 and over
    Angiogenesis Inhibitors
    Antibodies, Monoclonal
    Antibodies, Monoclonal, Humanized
    Bevacizumab
    Choroidal Neovascularization
    Disease Progression
    Drug Administration Schedule
    Exudates and Transudates
    Female
    Fluorescein Angiography
    Follow-Up Studies
    Humans
    Injections
    Macular Degeneration
    Male
    Middle Aged
    Retina
    Retinal Detachment
    Tomography, Optical Coherence
    Treatment Outcome
    Visual Acuity
    Vitreous Body

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    18937801

    Citation

    Krebs, Ilse, et al. "Efficacy of Intravitreal Bevacizumab (Avastin) Therapy for Early and Advanced Neovascular Age-related Macular Degeneration." Acta Ophthalmologica, vol. 87, no. 6, 2009, pp. 611-7.
    Krebs I, Lie S, Stolba U, et al. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol. 2009;87(6):611-7.
    Krebs, I., Lie, S., Stolba, U., Zeiler, F., Felke, S., & Binder, S. (2009). Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmologica, 87(6), pp. 611-7. doi:10.1111/j.1755-3768.2008.01312.x.
    Krebs I, et al. Efficacy of Intravitreal Bevacizumab (Avastin) Therapy for Early and Advanced Neovascular Age-related Macular Degeneration. Acta Ophthalmol. 2009;87(6):611-7. PubMed PMID: 18937801.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. AU - Krebs,Ilse, AU - Lie,Shilla, AU - Stolba,Ulrike, AU - Zeiler,Florian, AU - Felke,Stefan, AU - Binder,Susanne, Y1 - 2009/10/17/ PY - 2008/10/22/pubmed PY - 2009/11/11/medline PY - 2008/10/22/entrez SP - 611 EP - 7 JF - Acta ophthalmologica JO - Acta Ophthalmol VL - 87 IS - 6 N2 - PURPOSE: To evaluate the safety and efficacy of intravitreal bevacizumab therapy for early and advanced neovascular age-related macular degeneration (ARMD). METHODS: A consecutive series of eyes with neovascular ARMD treated with monthly intravitreal injections of bevacizumab (1.25 mg/0.05 ml) as long as there was evidence of activity on fluorescein angiography (FA) and optical coherence tomography (OCT) was included and observed for 6 months. For further analysis they were assigned to either an early (untreated/newly diagnosed) or an advanced (predominantly fibrotic/pre-treated) ARMD group. We examined distance visual acuity (VA) with Early Treatment Diabetic Retinopathy Study (ETDRS) charts and central retinal thickness with OCT, as well as lesion size and safety aspects. RESULTS: Forty-four patients (44 eyes) were enrolled (21 early lesions, 23 advanced lesions). Mean VA changed from 0.74 logMAR at baseline to 0.68 logMAR at month 6 (P = 0.01). Improvement in VA was statistically significant only in eyes with early lesions (n = 21) from month 1 (P = 0.015) up to month 6 (P = 0.03). The changes in central retinal thickness (CRT) (P < 0.001) and total lesion size (P < 0.001) were significant in both groups (early and advanced) at all time-points during follow-up. No significant ocular or systemic adverse effects were observed. CONCLUSION: Intravitreal bevacizumab was tolerated well by our patients and we did not identify any apparent short-term safety concerns. We observed stabilization in VA overall, with significant improvement in the early lesion group. SN - 1755-3768 UR - https://www.unboundmedicine.com/medline/citation/18937801/Efficacy_of_intravitreal_bevacizumab__Avastin__therapy_for_early_and_advanced_neovascular_age_related_macular_degeneration_ L2 - https://doi.org/10.1111/j.1755-3768.2008.01312.x DB - PRIME DP - Unbound Medicine ER -